Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | GYS1 | P13807 | 2/20 | 0.35 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.34 |
| ▸ | PPARG | P37231 | 2/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17614582 | 0.92 | GYS1 (0.34) | PTGS2FFAR1GYS1PPARG | |
| SCHEMBL16206012 | 0.91 | FFAR1 (0.37) | FFAR1ANO1PPARG | |
| SCHEMBL17614599 | 0.90 | GYS1 (0.40) | FFAR4FFAR1GYS1ANO1GABRG2 | |
| SCHEMBL17614598 | 0.90 | ANO1 (0.40) | FFAR4FFAR1GYS1ANO1GABRG2 | |
| SCHEMBL16206014 | 0.89 | FFAR1 (0.42) | FFAR1GYS1ANO1 | |
| SCHEMBL17614597 | 0.89 | GYS1 (0.37) | FFAR4FFAR1GYS1ANO1GABRG2 | |
| SCHEMBL16206009 | 0.89 | FFAR1 (0.37) | FFAR4FFAR1GYS1ANO1 | |
| SCHEMBL17614595 | 0.87 | FFAR1 (0.34) | FFAR1GYS1ANO1 | |
| SCHEMBL17614550 | 0.86 | SLC22A12 (0.39) | FFAR1GRIN1GRIN2BPPARGGABRG2 | |
| SCHEMBL16206015 | 0.86 | FFAR1 (0.41) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9867372-B2 | Tetrazolinone compound and use of same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-01-16 | — | — | US | disclosed |
| US-20160081339-A1 | TETRAZOLINONE COMPOUND AND USE OF SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160081339-A1 | TETRAZOLINONE COMPOUND AND USE OF SAME | MT-CO1, SOD1, MT-CO2 | FFAR4 2754/4885PTGS2 2986/4885FFAR1 1688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.